NASDAQ$ZNTL

Zentalis Pharmaceuticals Inc · Q2 2025 earnings

Q2 2025 earnings · · After market close · Investor relations

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS

-$0.37

Previous: -$1.24+70.2%
Capital Expenditures

$0.00

Previous: -$221K+100.0%
Free Cash Flow

-$26.9M

Previous: -$88.5M+69.6%
Net Income

-$26.9M

Previous: -$88.3M+69.6%
Operating Income

-$36.1M

Previous: -$65.1M+44.7%
Gross Profit

$400K

Previous: $2.95M-86.5%

Revenue & EPS history

Zentalis · Revenue · Quarterly

$0

Q2 2025
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q2 2025

Historical avgQ2 2025

-1.4%

Avg return

Earnings day

-2.0%

Avg return

5 days after

+0.8%

Avg return

30 days after

60%

15 / 25 earnings

Positive

+14.5%

Q1 2023

Best reaction

-43.0%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+3.1%-3.2%
Q1 2026+3.9%-1.7%-15.0%
Q3 2025+6.2%+0.8%+9.8%
Q2 2025+5.1%+2.2%+26.8%
Q1 2025-2.5%+3.3%+10.7%
Q4 2024-12.6%-15.0%-23.5%
Q3 2024-2.7%-13.9%-22.3%
Q2 2024-8.8%-12.5%-10.6%
Q1 2024+6.1%+7.0%-5.5%
Q4 2023+10.0%+8.5%+11.9%
Q3 2023-43.0%-45.0%-33.1%
Q2 2023+5.3%+11.2%-0.5%
Q1 2023+14.5%+22.8%+2.7%
Q4 2022+1.2%-2.1%-9.1%
Q3 2022-14.1%-4.3%-17.4%
Q2 2022-0.1%-7.3%-8.1%
Q1 2022-16.4%-24.7%+1.3%
Q4 2021+7.6%+5.7%-3.2%
Q3 2021+0.8%-1.0%-8.8%
Q2 2021+4.9%+7.1%+39.0%
Q1 2021-4.6%-1.3%-9.0%
Q4 2020+1.4%-0.7%+45.7%
Q3 2020-5.6%-2.1%+36.3%
Q2 2020+1.0%+7.2%-10.6%
Q1 2020+4.5%+8.2%+10.5%
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro